PURPOSE: Hepatorenal syndrome (HRS) is a pre-renal-like dysfunction that generally onsets in cirrhotic patients presenting ascites. We investigated the improvement of renal function in subjects with hepatorenal syndrome after terlipressin administration and the survival times after this treatment. Fifty-two patients affected by cirrhosis, with diagnosis of hepatorenal syndrome were treated with intravenous terlipressin plus albumin (group A) or with albumin alone (group B). Liver and renal function, plasma renin activity, and aldosterone plasma levels were monitored. RESULTS: Patients from group A showed a significant improvement (p < 0.001) of renal function valued by creatinine rate compared with the results obtained in group B. The probability of survival was higher in the group A (p < 0.0001). CONCLUSIONS: Our results seem to confirm that the administration of terlipressin plus albumin improves renal function in patients with cirrhosis and type I HRS and that a reversal of hepatorenal syndrome is strongly associated with improved survival.
PURPOSE:Hepatorenal syndrome (HRS) is a pre-renal-like dysfunction that generally onsets in cirrhotic patients presenting ascites. We investigated the improvement of renal function in subjects with hepatorenal syndrome after terlipressin administration and the survival times after this treatment. Fifty-two patients affected by cirrhosis, with diagnosis of hepatorenal syndrome were treated with intravenous terlipressin plus albumin (group A) or with albumin alone (group B). Liver and renal function, plasma renin activity, and aldosterone plasma levels were monitored. RESULTS:Patients from group A showed a significant improvement (p < 0.001) of renal function valued by creatinine rate compared with the results obtained in group B. The probability of survival was higher in the group A (p < 0.0001). CONCLUSIONS: Our results seem to confirm that the administration of terlipressin plus albumin improves renal function in patients with cirrhosis and type I HRS and that a reversal of hepatorenal syndrome is strongly associated with improved survival.
Authors: J Uriz; P Ginès; A Cárdenas; P Sort; W Jiménez; J M Salmerón; R Bataller; A Mas; M Navasa; V Arroyo; J Rodés Journal: J Hepatol Date: 2000-07 Impact factor: 25.083
Authors: V Arroyo; P Ginès; A L Gerbes; F J Dudley; P Gentilini; G Laffi; T B Reynolds; H Ring-Larsen; J Schölmerich Journal: Hepatology Date: 1996-01 Impact factor: 17.425
Authors: Thomas D Boyer; Arun J Sanyal; Guadalupe Garcia-Tsao; Frederick Regenstein; Lorenzo Rossaro; Beate Appenrodt; Veit Gülberg; Samuel Sigal; Alice S Bexon; Peter Teuber Journal: Liver Transpl Date: 2011-11 Impact factor: 5.799
Authors: Anna Licata; Marcello Maida; Ambra Bonaccorso; Fabio Salvatore Macaluso; Maria Cappello; Antonio Craxì; Piero Luigi Almasio Journal: World J Hepatol Date: 2013-12-27
Authors: Juan P Arab; Juan C Claro; Juan P Arancibia; Jorge Contreras; Fernando Gómez; Cristian Muñoz; Leyla Nazal; Eric Roessler; Rodrigo Wolff; Marco Arrese; Carlos Benítez Journal: World J Hepatol Date: 2016-09-08